Hydroxyacid Oxidase-1/HAO-1 Antibody (OTI5C3) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-71954PE
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat, Canine, Monkey, Primate
Applications
CyTOF-ready, Flow Cytometry, Western Blot
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI5C3
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full length recombinant protein of human Hydroxyacid Oxidase-1/HAO-1 (NP_060015) produced in HEK293T cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Hydroxyacid Oxidase-1/HAO-1 Antibody (OTI5C3) [PE]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Hydroxyacid Oxidase-1/HAO-1
Alternate Names
GOX, HAO-1, HAO1, HAOX1, Hydroxyacid Oxidase1
Gene Symbol
HAO1
Additional Hydroxyacid Oxidase-1/HAO-1 Products
Product Documents for Hydroxyacid Oxidase-1/HAO-1 Antibody (OTI5C3) [PE]
Product Specific Notices for Hydroxyacid Oxidase-1/HAO-1 Antibody (OTI5C3) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...